ERBB2 and breast carcinoma: For example, ICAM‐1‐decorated EV loaded with miR‐146a and Glut1, designed by Duarte‐Sanmiguel et al., can drive immunomodulation and hinder tumor progression in a breast cancer model.[10] Similarly, by engineering exosomes through genetic display of both anti‐human CD3 and anti‐human HER2 antibodies, the resultant synthetic multivalent antibodies retargeted exosomes (SMART‐Exos), dually target T cell CD3 and breast cancer‐associated HER2 receptors and exhibit highly potent and specific anti‐tumor activity both in vitro and in vivo.[11]